Dosimetry

CNL Announces 2023 Awards of Excellence Winners

Retrieved on: 
Monday, December 4, 2023
Hydrogen, First Nations, Science, Government, Radiation protection, ERM, Environmental remediation, Software, Research, Executive, Acquisition, Dosimetry, Chalk River Laboratories, Germania Hall, Growth, CNL, Safety, Isotopes of radium, Actinium-225, Nursing

CHALK RIVER, Ontario, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology organization, is pleased to announce that over 250 CNL employees were recognized for exceptional organizational accomplishments at the company’s 2023 Awards of Excellence ceremony, which was held last week at Germania Hall in Pembroke.

Key Points: 
  • CHALK RIVER, Ontario, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology organization, is pleased to announce that over 250 CNL employees were recognized for exceptional organizational accomplishments at the company’s 2023 Awards of Excellence ceremony, which was held last week at Germania Hall in Pembroke.
  • An annual program that recognizes employee excellence, the CNL Awards of Excellence were established to celebrate the outstanding achievements of individuals and teams whose hard work, determination and accomplishments helped CNL deliver its science and technology programs and major projects.
  • “The 2023 CNL Awards of Excellence winners come from various departments and sites all across the company, and the work that they do is diverse, requires unique strengths, and spans different work environments,” commented Joe McBrearty, CNL’s President and CEO.
  • For a full list of the 2023 CNL Awards of Excellence winners, including profiles and videos on the award-winning teams, please visit www.cnl.ca/awards .

Novocure Announces Presence at American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting

Retrieved on: 
Friday, September 29, 2023
Biotechnology, Radiology, Health, Oncology, Real, GBM, Body mass index, Effect, ASTRO, Topical medication, Survival, Skin, Meta-analysis, Radiation treatment planning, Radiation therapy, Patient, Lung, Science in newly industrialized countries, Annual general meeting, Systematic review, Neoplasm, Epigastrium, BMI, Society, Treatment, American Society for Radiation Oncology, Software, Medical imaging, Medical device, Pharmaceutical industry, Communications satellite, Glioblastoma, Dosimetry

Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego.
  • Results support the feasibility of TTFields therapy delivery to the lungs regardless of BMI and highlight the importance of choosing the appropriate array size for each patient.
  • “We are committed to continuous innovation, and we look forward to sharing new insights about the use of TTFields therapy with the scientific community,” said Pritesh Shah, Novocure’s Chief Growth Officer.
  • Tumor Treating Fields (TTFields) in the Real World for Newly Diagnosed Glioblastoma: A Survival Meta-analysis With Systematic Review.

NATS USA and partner company Radiation Detection Systems (RDS) participates at National Health Physics Meeting at the Nation's Capital

Retrieved on: 
Monday, August 7, 2023
Radiation, National Harbor, Maryland, RD (group), NATS, TACTIC (military program), Convention center, Gaylord National Resort & Convention Center, Drone, Tactical Robotics Cormorant, Conventional weapon, Tactic, RDS, Conference, Medical imaging, Dosimetry, Chemical substance

FORT WASHINGTON, Md., Aug. 7, 2023 /PRNewswire-PRWeb/ -- The NATS RDS booth was well attended. Prime among the displays at the NATS RDS booth were new NATS RDS solutions for mobile survey and inspection using intelligent Drones and Tactical Robots using multiple sensors. These solutions involve using advanced drones of various payload with radiation, chemical, and thermal imaging sensors. The systems are complimented with advanced ground control and mapping software. These systems now complete the NATS CBRNE solutions including capabilities for rai radiation, toxic industrial chemicals, chemical warfare agents, and explosive detection solutions.

Key Points: 
  • NATS USA and Radiation Detection Systems USA (RDS) participated with a widely attended booth at the National Health Physics Meeting near the nation's capital in Washington D.C. NATS RDS Group participated at the National Health Physics meeting at the Gaylord National Resort and Conference Center at the National Harbor in Maryland, USA on July 23-27, 2023.
  • NATS RDS display featured a large number of products including intelligent drones and tactical robots for radiation and Chemical detection.
  • These systems now complete the NATS CBRNE solutions including capabilities for rai radiation, toxic industrial chemicals, chemical warfare agents, and explosive detection solutions.
  • [email protected] , NATS USA INC., 1 8603980035, [email protected] , NATS USA INC.

MTTI Highlights Promising One-Year Follow-Up on EBTATE Treatment of Neuroendocrine Cancer Patients Without Amino Acid Infusion

Retrieved on: 
Wednesday, June 21, 2023
Oncology, Health, General Health, Radiology, Clinical Trials, Pharmaceutical, Biotechnology, GFR, Hyperkalemia, Carcinoma, Radiation, Nephrotoxicity, Biodistribution, Blood urea nitrogen, Dosimetry, Half-life, Creatinine, Overalls, Quality of life, Glomerular filtration rate, NET, Dicarboxylic acid, Vomiting, Serum albumin, MD, Patient, Cancer, Kidney, Creatine, Nausea, BUN, PRRT, Phosphorus, Dietary supplement, Safety

Molecular Targeting Technologies, Inc. (MTTI) announced promising results from a 1-year follow-up on EBTATE (2 cycles, 3.7 GBq/cycle) treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) without amino acid pretreatment.

Key Points: 
  • Molecular Targeting Technologies, Inc. (MTTI) announced promising results from a 1-year follow-up on EBTATE (2 cycles, 3.7 GBq/cycle) treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) without amino acid pretreatment.
  • A 4-hour long amino acid cocktail infusion reduces renal absorbed radiation dose, with significant side effects like nausea, vomiting and hyperkalemia.
  • EBTATE administration appears to be safe without amino acid infusion.”
    Chris Pak, President & CEO of MTTI commented, “Amino acid infusion impacts quality of life, access to care, patient compliance to treatment and overall treatment costs.
  • Evaluation of Safety, Biodistribution and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE (EBTATE) with and without Amino Acid Infusion.

POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy

Retrieved on: 
Tuesday, November 29, 2022
COVID-19, PDX, Patient, Syngenic, DNA repair, DNA, CMC, Melanoma, Actinium-225, Dosimetry, Optimism, Annual report, SPLASH, TRADD, MCRPC, Neoplasm, Molecular imaging, Cell death, Cancer, RLT, Prostate cancer, Clinical trial, FAP, Immunotherapy, Safety, Pharmaceutical industry, Tolerability

INDIANAPOLIS, Nov. 29, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today released new preclinical data from the Company’s pan-cancer fibroblast activation protein-α (FAP-α) targeted program, PNT2004.

Key Points: 
  • The preclinical study focused on assessing the potential of the lead candidate in the PNT2004 clinical program, 177Lu-PNT6555, in combination with anti-PD-1 immunotherapy.
  • The CT26-mFAP tumor model used expresses low levels of FAP, grows aggressively, and is insensitive to anti-PD-1 immunotherapy.
  • The study found that combination treatment with 177Lu-PNT6555 and anti-PD-1 resulted in a significant survival benefit, as compared to either treatment independently.
  • The new preclinical data from the study can be found in an updated investor presentation available on the investors section of the Companys website.

POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings

Retrieved on: 
Monday, November 14, 2022
Clinical trial, EOY, Common stock, LNTH, Molecular imaging, Cancer, Safety, Food and Drug Administration, ESMO, Growth, RLT, Investment, Administration, Prostate cancer, Actinium-225, Development, COVID-19, European Association of Urology, Patient, FDA, Sarcoma, Poster, MCRPC, RPF, Melanoma, Toxicity, Pharmacokinetics, Dosimetry, EANM, Progression-free survival, Annual report, Food, SPLASH, PSMA, Nuclear medicine, Research, Pharmaceutical industry, Medical imaging, Life insurance, Animal, Tolerability

Additionally, Lantheus will pay POINT royalties on net sales, beyond certain financial thresholds and subject to conditions, of 20% for PNT2002 and 15% for PNT2003.

Key Points: 
  • Additionally, Lantheus will pay POINT royalties on net sales, beyond certain financial thresholds and subject to conditions, of 20% for PNT2002 and 15% for PNT2003.
  • We are very pleased to have reported the Lantheus strategic collaboration earlier this morning.
  • With our financial position further strengthened, we can continue to focus on our core competencies and dedicate resources to our pipeline.
  • In October 2022, POINT published promising new pre-clinical data from the Companys next-generation radioligand therapy (RLT) program for prostate cancer, PNT2001.

Ashvattha Therapeutics Announces Preclinical Data on Hydroxyl Dendrimer Based PET Tracer [18F]OP-801 Presented at the 2022 World Molecular Imaging Congress

Retrieved on: 
Thursday, September 29, 2022
Neuro, Plasma, Therapy, Inflammation, Multiple sclerosis, Spinal cord, Lists of diseases, Nanomedicine, QC, Microglia, Biomarker, HDS, Miami Beach Convention Center, Neurodegeneration, Quality control, Diabetic retinopathy, Macrophage, DME, HDT, Mouse, MS, Patient, PET, EAE, CEO, Ashvattha, Doctor of Philosophy, Johns Hopkins University, Traffic barrier, Autoradiograph, Neurology, Stanford University, ALS, AMD, GLOBE, HD, Neuroinflammation, Dosimetry, Disease, Radiology, Pharmaceutical industry, Medical imaging, Marketing, Trapping, Ophthalmology, CSF1R

REDWOOD CITY, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel hydroxyl dendrimer therapeutics, today announced preclinical data presented by collaborators from Stanford University demonstrating that its hydroxyl dendrimer (HD)-based PET tracer, [18F]OP-801, can detect activated macrophages and microglia with high sensitivity and specificity in an experimental autoimmune encephalomyelitis (EAE) murine model of multiple sclerosis (MS), in addition to being reproducibly synthesized and suitable for human use. The data were presented at the World Molecular Imaging Congress being held September 28th – October 1st, 2022, at the Miami Beach Convention Center in Miami, FL.

Key Points: 
  • The data were presented at the World Molecular Imaging Congress being held September 28th October 1st, 2022, at the Miami Beach Convention Center in Miami, FL.
  • PET imaging data was corroborated by autoradiography images, showing significantly higher signal in the lumbar spinal cord of untreated compared to treated EAE mice.
  • Human dosimetry estimates based on mouse imaging data are conducive to translation and clinical imaging of [18F]OP-801.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology.

Radiation Detection Company Brings On Former Landauer VP Chris Passmore as Chief Technology Officer

Retrieved on: 
Wednesday, July 6, 2022
Health, Technology, Hospitals, Other Health, General Health, Radiology, Hardware, CEO, Radiation protection, Landauer, Growth, RDC, Industry, Chris, NVLAP, Radiation monitoring, Investment, Leadership, Management, Dosimetry

Radiation Detection Company [RDC] today announced the executive appointment of Chris Passmore as RDCs new Chief Technology Officer.

Key Points: 
  • Radiation Detection Company [RDC] today announced the executive appointment of Chris Passmore as RDCs new Chief Technology Officer.
  • Radiation Detection Company continues to make significant investments in their dosimetry service, and I am extremely impressed with the leadership, company culture, corporate vision, and the significant growth and profitability achieved under Ryan Turks leadership, says Chris.
  • I am excited for Chris to join my Executive team in this key role, says Ryan Turk, CEO at Radiation Detection Company.
  • Radiation Detection Company has provided quality dosimetry service with unmatched reliability since 1949 through its NVLAP accredited dosimetry service [NLVAP lab code 100512-0].

Fusion Pharmaceuticals Presents Imaging Data from Cold Antibody Sub-Study in the Phase 1 Study of FPI-1434

Retrieved on: 
Tuesday, June 14, 2022
Pembrolizumab, Antibody, SNMMI, Half-life, Review, Security (finance), Dosimetry, AstraZeneca, COVID-19, GMP, U.S. Securities and Exchange Commission, Safety, Toxicity, Therapeutic index, Neurotensin receptor, McMaster University, Society, View, Liver, Lymph, Fusion, Tat, Company, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Pharmacokinetics, Forward-looking statement, Research, Private Securities Litigation Reform Act, Isotope, Merck, DNA, Neoplasm, Disease, Lung, IND, SEC, Radiopharmaceutical, FGFR3, Society of Nuclear Medicine and Molecular Imaging, Coronavirus, Molecular imaging, Multimedia, Good manufacturing practice, Annual general meeting, NTSR1, Actinium-225, Medical imaging, Vaccine, Pharmaceutical industry, Patient

HAMILTON, ON and BOSTON, June 14, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of imaging data from the "cold antibody sub-study" evaluating pre-administration of cold antibody (naked antibody without the isotope) prior to administration of the imaging agent (antibody with the isotope) in the Phase 1 study of FPI-1434 for the treatment of solid tumors expressing IGF-1R. Data were presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting in a presentation titled "Impact of Pre-Administration of Anti-IGF-1R Antibody FPI-1175 on the Dosimetry, Tumor Uptake, and Pharmacokinetics of the IGF-1R Targeted Theranostic Imaging Agent [111In]-FPI-1547 in Patients with Solid Tumors".

Key Points: 
  • The cold antibody sub-study was conducted concurrently with the dose escalation portion of the Phase 1 study of FPI-1434 for the treatment of solid tumors.
  • Imaging data from the study demonstrate a favorable gain in [111In]-FPI-1547 tumor lesion uptake versus normal tissue when FPI-1175 was pre-administered and compared to dosing with FPI-1547 alone.
  • Dr. Valliant continued, "These data from the cold antibody sub-study strengthen our understanding of this dosing regimen and support further evaluation.
  • As a result, Fusion encourages investors, media and others interested to review the information that Fusion posts there on a regular basis.

Molecular Targeting Technologies, Inc. Features EBTATE Advances at The 2022 SNMMI Meeting In Vancouver, BC

Retrieved on: 
Thursday, June 9, 2022
Biotechnology, Health, Oncology, Clinical Trials, SNMMI, Large-cell lung carcinoma, PET, Cell death, Glioblastoma, Society, Cancer, Society of Nuclear Medicine and Molecular Imaging, Biodistribution, Nen language (Papuan), 2021 Essex County Council election, Dosimetry, Health, Molecular imaging, Medical imaging, Safety, BC

Molecular Targeting Technologies, Inc. (MTTI), a clinical stage oncology company, will highlight advances on its EvaTheraTM radiotheranostics platform at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting in Vancouver, BC, on June 11-15, 2022 (Exhibit booth #1715).

Key Points: 
  • Molecular Targeting Technologies, Inc. (MTTI), a clinical stage oncology company, will highlight advances on its EvaTheraTM radiotheranostics platform at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting in Vancouver, BC, on June 11-15, 2022 (Exhibit booth #1715).
  • The EvaThera platform includes EBTATETM (177Lu-DOTA-EB-TATE) for Neuroendocrine Neoplasms (NENs), Hrthle cell thyroid and nasopharyngeal cancers and EBRGDTM (177Lu-DOTA-EB-RGD) for glioblastoma multiforme and non-small cell lung cancer
    A video featuring the EBTATE story (see link below) will be released at the meeting.
  • MTTI is a privately held, rapidly growing, well financed, clinical stage biotech developing targeted radiotherapeutics and diagnostics for rare cancers.
  • We are committed to building value by acquiring and translating innovative imaging, radiopharmaceutical and theranostic assets to improve human health, reduce healthcare costs and reward stakeholders.